Acceleron Selected as One of Boston Business Journal’s 2009 Best Places to Work

CAMBRIDGE, Mass. – May 1, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle, red blood cells, and vasculature, today announced that it has been selected as one of the 2009 Best Places to Work by the Boston Business Journal. The award recognizes the company's achievements in creating a positive work environment that attracts and retains employees through a combination of employee satisfaction, work conditions and company culture.

“Acceleron is honored to be recognized by the Boston Business Journal as one of the 2009 Best Places to Work,” said John Knopf, Ph.D., Chief Executive Officer and Founder of Acceleron. “We are committed to creating and maintaining a corporate culture that enables our rapidly expanding workforce to be highly productive, enjoy their work and take deep pride in their contributions to advancing science and products to improve the lives of patients.”

About Acceleron

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, red blood cells, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the Growth and Differentiation Factor (GDF) family of proteins. ACE-011 is currently being studied in a Phase 2 clinical trial in multiple myeloma patients with osteolytic bone disease. ACE-031 is currently being studied in a Phase 1 clinical trial in healthy volunteers. In addition, the company is advancing new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase hemoglobin. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Bessemer Ventures, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com.

CONTACT:
Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development

Paul Kidwell (Media)
Suda Communications LLC, tel: 617-296-3854

BACK TO PRESS RELEASES